Novavax lauds Health and Human Services countermeasures plan

Rahul Singhvi, Novovax, Inc.'s president and CEO, has come out in support of the U.S. Department of Health and Human Services Secretary Kathleen Sebelius after she announced her plan to fund a $2 billion initiative to accelerate the production of medical countermeasures in an emergency.

Sebelius held a news conference on August 19 in Washington, D.C., to discuss the release of "The Public Health Emergency Medical Countermeasures Enterprise Review: Transforming the Enterprise to Meet Long-range National Needs."

“I was pleased to attend today's briefing by Secretary Sebelius and fully support the reforms proposed to improve our nation's ability to respond to disease outbreaks such as pandemic influenza,” Dr. Singhvi said. “My colleagues at Novavax and I share the government's sense of urgency about accelerating the development and delivery of new vaccines to prevent the spread of infectious diseases as a result of a natural outbreak or a biological attack and have committed our company to the achievement of this goal.” 

The new report is essentially both a blueprint of the current process of countering the existence of unknown threats and a look at how it will be transformed in the near future to improve medical responses in health crises.

Included in the strategy are upgrades to the regulatory capacity of the Food and Drug Administration, the development of faster manufacturing processes that could be used for multiple vaccines, the creation of technology teams at the National Institutes of Health to identify promising research, the fostering of young biotech companies to develop new countermeasures and upgrades to the existing process of influenza vaccine manufacture.

"We believe our unique recombinant technology can help play a key role in solving the problems of vaccine supply, timely preparation and availability and that our vaccines have the potential to prevent the spread of seasonal and pandemic influenza, including H1N1, and other infectious diseases described in today's report,” Singhva said. “The proposal to create more rapid and flexible U.S. manufacturing capabilities and use new production technologies to transform our nation's response capability is perfectly aligned with our company's technology focus and commercial strategy and we support its adoption."

Organizations in this story

National Institutes of Health 9000 Rockville Pike Bethesda, MD 20892

Get notified the next time we write about National Institutes of Health!